Concerted transcriptional regulation by BRCA1 and COBRA1 in breast cancer cells

International Journal of Biological Sciences

Volumn 3, Issue 7, 2007, Pages 486-492

  Aiyar, Sarah E ^a   Cho, HyungJun ^a   Lee, Jae ^a   Li, Rong ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b University of Texas Health Science Center   (United States)

Author keywords

BRCA1; Breast cancer; COBRA1; shRNA knockdown; Transcription regulation

Indexed keywords

BRCA1 PROTEIN; COBRA1 PROTEIN; ESTROGEN; GENE PRODUCT; NUCLEAR PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SUSCEPTIBILITY; ENZYME REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE CULTURE CELL; TRANSCRIPTION REGULATION;

EID: 37249070497     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.3.486     Document Type: Article

References (35)

1. Ye Q, Hu Y-F, Zhong H, Nye AC, Belmont AS and Li R. BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations. J. Cell Biol. 2001; 155: 911-921.
2. Narita T, Yamaguchi Y, Yano K, Sugimoto S, Chanarat S, Wada T, Kim D-K, Hasegawa J, Omori M, Inukai N, Endoh M, Yamada T and Handa H. Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex. Mol. Cell. Biol. 2003; 23: 1863-1873.
3. Wada T, Takagi T, Yamaguchi Y, Ferdous A, Imai T, Hirose H, Sugimoto S, Hartzog GA, Winston F, Buratowski S and Handa H. DSIF, a novel transcription elongation factor that regulates RNA polymeerase II processitivity, is composed of human Spt4 and Spt5 homologs. Genes & Dev. 1998; 12: 343-356.
4. Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, Hasegawa J and Handa H. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 1999; 97: 41-51.
5. Aiyar SE, Sun J-L, Blair AL, Moskaluk CA, Lv Y, Ye Q-N, Yamaguchi Y, Mukherjee A, Ren D-M, Handa H and Li R. Attenuation of estrogen receptor alpha-mediated transcription through estrogen-stimulated recruitment of a negative elongation factor. Genes & Dev. 2004; 18: 2134-2146.
6. Aiyar SE, Blair AL, Hopkinson DA, Bekiranov S and Li R. Regulation of clustered gene expression by cofactor of BRCA1 (COBRA1) in breast cancer cells. Oncogene. 2007; 26: 2543-2553.
7. Zhu J, Song S, Jiang Z, Yan J, Lu Q, Huang C and Ye Q. Characterization of COBRA1 in human breast cancer cell lines using a new polyclonal antibody against COBRA1. IUBMB Life. 2004; 56: 161-166.
8. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID and Rosen EM. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284(5418): 1354-6.
9. Zheng L, Annab LA, Afshari CA, Lee W-H and Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl. Acad. Sci. USA 2001; 98: 9587-9592.
10. Neish AS, Anderson SF, Schlegel BP, Wei W and Parvin JD. Factors associated with the mammalian RNA polymerase II holoenzyme. Nucleic Acids Res 1998; 26(3): 847-53.
11. Yamaguchi Y, Inukai N, Narita T, Wada T and Handa H. Evidence that negative elongation factor represses transcription elongation through binding to a DRB sensitivity-inducing factor/RNA polymerase II complex and RNA. Mol. Cell. Biol. 2002; 22: 2918-2927.
12. Cabart P, Chew HK and Murphy S. BRCA1 cooperates with NUFIP and P-TEFb to activate transcription by RNA polymerase II. Oncogene 2004; 23: 5316-5329.
13. Krum SA, Miranda GA, Lin C and Lane TF. BRCA1 associates with processive RNA polymerase II. J. Biol. Chem. 2003; 278: 52012-52020.
14. Jain N, Thatte J, Braciale T, Ley K, O'Connell M and Lee JK. Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics. 2003; 19: 1945-1951.
15. Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, Jones A, Simpson P, Harris RA, Jat PS, Neville AM, Reis LF, Lakhani SR and O'Hare MJ. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 2003; 22: 2680-2688.
16. Nakopoulou L, Giannopoulou I, Lazaris AC, Alexandrou P, Tsirmpa I, Markaki S, Panayotopoulou E and Keramopoulos A. The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 2003; 111: 1027-1036.
17. Clavel C, Polette M, Doco M, Binninge I and Birembaut P. Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology. Bull Cancer 1992; 79: 261-270.
18. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, Brunner N and Stephens RW. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer. 1999; 80: 495-503.
19. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N and Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer. 1999; 84: 44-48.
20. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Gilles L, Burn JL, Colpaert C, van Dam P, Van Marck EA, Dirix LY and Vermeulen PB. Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer. Clin Exp Metastasis. 2007; [Epub ahead of print].
21. Chen B, Wen Y, Wang H and Polan ML. Differences in estrogen modulation of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-1 expression in cultured fibroblasts from continent and incontinent women. Am J Obstet Gynecol. 2003; 189: 59-65.
22. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J and Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl. Cancer Inst. 2002; 94: 990-1000.
23. Jazaeri AA, Chandramouli GVR, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, Ropers HH, Yee CJ, Boyd J and Barrett JC. BRCA1-mediated repression of select X chromosome genes. J. Translational Med. 2004; 2: 32-39.
24. Hesling C, D'Incan M, D'Incan C, Souteyrand P, Monboisse JC, Pasco S, Madelmont JC and Bignon YJ. Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression. J Invest Dermatol. 2004; 122: 369-380.
25. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW and Foekens JA. Genes Associated With Breast Cancer Metastatic to Bone. J Clin Oncol. 2006; 24: 2261-2267.
26. Vestergaard EM, Borre M, Poulsen SS, Nexo E and Torring N. Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res. 2006; 12: 807-812.
27. Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R and Rudland PS. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 2006; 66: 1199-1207.
28. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF and Ellis IO. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005; 18: 195-304.
29. Sun J, Watkins G, Blair AL, Moskaluk C, Ghosh S, Jiang WG and Li R. Deregulation of cofactor of BRCA1 expression in breast cancer cells. J Cell Biochem. 2007; [Epub ahead of print].
30. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM and Parvin JD. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 1997; 94(11): 5605-10.
31. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES and Parvin JD. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 1998; 19: 254-256.
32. Kleiman FE and Manley JL. Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50. Science 1999; 285: 1329-1339.
33. Kleiman FE and Manley JL. The BARD1-CstF-50 interaction links mRNA 3′ end formation to DNA damage and tumor suppression. Cell 2001; 104: 743-753.
34. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H. HBCCS. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356: 1876-1881.
35. Albiges L, Andre F, Balleyguier C, Gomez-Abuin G, Chompret A and Delaloge S. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol. 2005; 16: 1846-1847.